215 related articles for article (PubMed ID: 28207525)
1. Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy.
Zhao J; Zhang P; Wang J; Xi Q; Zhao X; Ji M; Hu G
Medicine (Baltimore); 2017 Feb; 96(7):e6102. PubMed ID: 28207525
[TBL] [Abstract][Full Text] [Related]
2. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S
Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759
[TBL] [Abstract][Full Text] [Related]
3. Serum Amyloid P-component Level May be a Biomarker for Lung Toxicities and Overall Survival after Thoracic Radiotherapy for Non-small Cell Lung Cancer.
Zhao J; Chi A; Mao R; Hu G; Ji M
Clin Lab; 2016 Nov; 62(11):2183-2190. PubMed ID: 28164664
[TBL] [Abstract][Full Text] [Related]
4. Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody.
Murakami S; Shibaki R; Matsumoto Y; Yoshida T; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Ohe Y
Thorac Cancer; 2020 Dec; 11(12):3585-3595. PubMed ID: 33108686
[TBL] [Abstract][Full Text] [Related]
5. The correlation of serum sPD-1 and sPD-L1 levels with clinical, pathological characteristics and lymph node metastasis in nonsmall cell lung cancer patients.
Ancın B; Özercan MM; Yılmaz YM; Uysal S; Kumbasar U; Sarıbaş Z; Dikmen E; Doğan R; Demircin M
Turk J Med Sci; 2022 Aug; 52(4):1050-1057. PubMed ID: 36326416
[TBL] [Abstract][Full Text] [Related]
6. The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes.
Ding XC; Wang LL; Zhu YF; Li YD; Nie SL; Yang J; Liang H; Weichselbaum RR; Yu JM; Hu M
Front Immunol; 2020; 11():580335. PubMed ID: 33224142
[TBL] [Abstract][Full Text] [Related]
7. Molecular Mechanism of Expression Changes of Immunological Indexes of PD-1/sPD-L1 after Radiotherapy in Nonsmall Cell Lung Cancer.
Qu Y; Wang H; Liu H; Sun X; Li J; Yu H
Biomed Res Int; 2021; 2021():8811751. PubMed ID: 33987445
[TBL] [Abstract][Full Text] [Related]
8. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.
Okuma Y; Hosomi Y; Nakahara Y; Watanabe K; Sagawa Y; Homma S
Lung Cancer; 2017 Feb; 104():1-6. PubMed ID: 28212990
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients.
Li C; Li C; Zhi C; Liang W; Wang X; Chen X; Lv T; Shen Q; Song Y; Lin D; Liu H
J Transl Med; 2019 Oct; 17(1):355. PubMed ID: 31665020
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
Tominaga T; Akiyoshi T; Yamamoto N; Taguchi S; Mori S; Nagasaki T; Fukunaga Y; Ueno M
PLoS One; 2019; 14(2):e0212978. PubMed ID: 30807610
[TBL] [Abstract][Full Text] [Related]
11. Study on the Expression Levels and Clinical Significance of PD-1 and PD-L1 in Plasma of NSCLC Patients.
He J; Pan Y; Guo Y; Li B; Tang Y
J Immunother; 2020 Jun; 43(5):156-164. PubMed ID: 32168233
[TBL] [Abstract][Full Text] [Related]
12. Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy.
Brun SS; Hansen TF; Wen SWC; Nyhus CH; Bertelsen L; Jakobsen A; Hansen TS; Nederby L
Sci Rep; 2024 Apr; 14(1):8993. PubMed ID: 38637655
[TBL] [Abstract][Full Text] [Related]
13. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
[TBL] [Abstract][Full Text] [Related]
14. The influence of plasma sPD-L1 concentration on the effectiveness of immunotherapy in advanced NSCLC patients.
Chmielewska I; Grenda A; Krawczyk P; Frąk M; Kuźnar Kamińska B; Mitura W; Milanowski J
Cancer Immunol Immunother; 2023 Dec; 72(12):4169-4177. PubMed ID: 37816808
[TBL] [Abstract][Full Text] [Related]
15. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
[TBL] [Abstract][Full Text] [Related]
16. Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study.
Tiako Meyo M; Jouinot A; Giroux-Leprieur E; Fabre E; Wislez M; Alifano M; Leroy K; Boudou-Rouquette P; Tlemsani C; Khoudour N; Arrondeau J; Thomas-Schoemann A; Blons H; Mansuet-Lupo A; Damotte D; Vidal M; Goldwasser F; Alexandre J; Blanchet B
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32085544
[TBL] [Abstract][Full Text] [Related]
17. Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib.
Sorensen SF; Demuth C; Weber B; Sorensen BS; Meldgaard P
Lung Cancer; 2016 Oct; 100():77-84. PubMed ID: 27597284
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma.
Wang L; Wang H; Chen H; Wang WD; Chen XQ; Geng QR; Xia ZJ; Lu Y
Oncotarget; 2015 Dec; 6(38):41228-36. PubMed ID: 26515600
[TBL] [Abstract][Full Text] [Related]
19. Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer.
Takeuchi M; Doi T; Obayashi K; Hirai A; Yoneda K; Tanaka F; Iwai Y
Immunol Lett; 2018 Apr; 196():155-160. PubMed ID: 29366663
[TBL] [Abstract][Full Text] [Related]
20. Plasma sPD-L1 and VEGF levels are associated with the prognosis of NSCLC patients treated with combination immunotherapy.
Dong C; Hui K; Gu J; Wang M; Hu C; Jiang X
Anticancer Drugs; 2024 Jun; 35(5):418-425. PubMed ID: 38386011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
